Your browser doesn't support javascript.
loading
Antimicrobial Activity of Omadacycline Tested against Clinical Bacterial Isolates from Hospitals in Mainland China, Hong Kong, and Taiwan: Results from the SENTRY Antimicrobial Surveillance Program (2013 to 2016).
Carvalhaes, Cecilia G; Huband, Michael D; Reinhart, Harald H; Flamm, Robert K; Sader, Helio S.
Affiliation
  • Carvalhaes CG; JMI Laboratories, North Liberty, Iowa, USA cecilia-carvalhaes@jmilabs.com.
  • Huband MD; JMI Laboratories, North Liberty, Iowa, USA.
  • Reinhart HH; Zai Lab (Shanghai) Co., Ltd., Pudong, Shanghai, China.
  • Flamm RK; JMI Laboratories, North Liberty, Iowa, USA.
  • Sader HS; JMI Laboratories, North Liberty, Iowa, USA.
Article in En | MEDLINE | ID: mdl-30617092
ABSTRACT
Omadacycline is a derivative of minocycline and the first agent of the aminomethylcycline class. A total of 3,282 organisms (1 per patient) were consecutively collected from patients hospitalized in China (including Hong Kong) and Taiwan. Susceptibility testing was performed by broth microdilution methods in a central laboratory (JMI Laboratories). The collection included Gram-positive and Gram-negative organisms from patients with pneumonia, bloodstream, skin, community-acquired respiratory, and other infections. Omadacycline was very potent against Staphylococcus aureus (n = 689; MIC50/90, 0.12/0.25 mg/liter), including methicillin-resistant Staphylococcus aureus (MRSA; n = 299; MIC50/90, 0.12/0.5 mg/liter), and had similar activity across geographic regions. Omadacycline was very active against Streptococcus pneumoniae (highest MIC, 0.25 mg/liter), ß-hemolytic streptococci (highest MIC, 1 mg/liter), viridans group streptococci (highest MIC, 0.25 mg/liter), and Enterococcus spp. (highest MIC, 0.5 mg/liter) from all geographic regions. Overall, 53.8% of S. pneumoniae isolates were penicillin resistant (penicillin MIC, ≥2 mg/liter) and 10.7% of enterococci (21.2% among E. faecium isolates) were vancomycin resistant. Omadacycline was active against Haemophilus influenzae (MIC50/90, 0.5/1 mg/liter) regardless of ß-lactamase production and was active against Moraxella catarrhalis (MIC50/90, ≤0.12/0.25 mg/liter). Against Enterobacteriaceae, omadacycline was most active against Escherichia coli (MIC50/90, 1/2 mg/liter), Klebsiella oxytoca (MIC50/90, 1/4 mg/liter), and Enterobacter cloacae (MIC50/90, 2/4 mg/liter). Omadacycline had potent in vitro activity against Gram-positive and Gram-negative pathogens isolated from China and Taiwan and retained activity against problem pathogens, such as MRSA, vancomycin-resistant enterococci (VRE), penicillin-resistant S. pneumoniae (PRSPN), and extended-spectrum ß-lactamase-producing E. coli The observed MIC profile in Chinese isolates was very similar to that seen in the U.S. and European surveillance studies.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tetracyclines / Bacterial Infections / Anti-Bacterial Agents Type of study: Screening_studies Limits: Humans Country/Region as subject: Asia Language: En Journal: Antimicrob Agents Chemother Year: 2019 Document type: Article Affiliation country: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tetracyclines / Bacterial Infections / Anti-Bacterial Agents Type of study: Screening_studies Limits: Humans Country/Region as subject: Asia Language: En Journal: Antimicrob Agents Chemother Year: 2019 Document type: Article Affiliation country: United States